Nimesulida Oara (Nimesulide)

Nimesulide, the active ingredient in Nimesulida Oara, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as an oral tablet for oral use. It is used to relieve mild to moderate pain, reduce inflammation and lower fever in adults. GNH USA supplies Nimesulida Oara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimesulida Oara, an NSAID, works within the prostaglandin pathway to manage several painful and inflammatory conditions.

- Mild to moderate pain: provides analgesia for headaches, dental pain, musculoskeletal aches, and postoperative discomfort. - Osteoarthritis and other inflammatory joint conditions: reduces swelling and improves joint function. - Dysmenorrhea: alleviates menstrual cramps and associated pelvic pain. - Fever: lowers elevated body temperature in acute febrile episodes.

Adverse reactions may range from mild, self‑limiting events to serious, potentially life‑threatening conditions.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain. - Headache or dizziness. - Skin rash or mild itching. - Elevated liver enzymes detected on routine labs. - Mild increase in blood pressure.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury or failure. - Gastrointestinal bleeding or ulcer perforation. - Severe skin reactions such as Stevens‑Johnson syndrome. - Renal impairment or acute kidney injury. - Anaphylactic or severe hypersensitivity reactions.

Before prescribing Nimesulida Oara, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Liver function: assess baseline enzymes and avoid use in patients with active hepatic disease. - Gastrointestinal risk: use cautiously in individuals with a history of ulcers or bleeding. - Renal function: adjust or avoid in severe renal impairment. - Cardiovascular safety: monitor blood pressure and avoid in uncontrolled hypertension. - Pediatric use: not recommended for children under 12 years of age. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nimesulida Oara can alter the pharmacokinetics or pharmacodynamics of several co‑administered medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Lithium: elevated lithium serum levels. - Methotrexate: reduced clearance leading to toxicity. - Cyclosporine: enhanced nephrotoxicity.

Moderate Interactions (Monitor Closely): - Antihypertensives (ACE inhibitors, ARBs, diuretics): possible reduction in antihypertensive effect. - SSRIs or SNRIs: heightened bleeding tendency. - Oral hypoglycemics: potential alteration of blood glucose control.